Inclusion of minorities and women in cancer clinical trials, a decade later: Have we improved?

Kat Kwiatkowski, Kathryn Coe, John C. Bailar, G. Marie Swanson

    Research output: Contribution to journalArticle

    53 Scopus citations

    Abstract

    BACKGROUND Inclusion of diverse groups of participants in cancer clinical trials is an important methodological and clinical issue. The quality of the science and generalizability of results depends on the inclusion of study participants who represent all populations among whom these treatment and prevention approaches will be used. METHODS We conducted a systematic review using OVID as the primary source of reports included. Based on 304 peer-reviewed publications, diversity in the inclusion and reporting of study participants during a decade of cancer treatment and prevention trials (2001-2010) is summarized. Recommendations are made for improvements in the science and reporting of cancer clinical trials. RESULTS Of the 277 treatment trials and 27 prevention trials included in this report, more than 80% of participants were white and 59.8% were male. In the recent decade, race and sex are rarely used as selection criteria unless the trial is focused on a sex-specific cancer. CONCLUSIONS Women and racial/ethnic minorities remain severely underrepresented in cancer clinical trials, thus limiting the generalizability of cancer clinical research.

    Original languageEnglish (US)
    Pages (from-to)2956-2963
    Number of pages8
    JournalCancer
    Volume119
    Issue number16
    DOIs
    StatePublished - May 20 2013

    Keywords

    • cancer clinical trials
    • health disparities
    • participant selection
    • prevention
    • treatment

    ASJC Scopus subject areas

    • Cancer Research
    • Oncology

    Fingerprint Dive into the research topics of 'Inclusion of minorities and women in cancer clinical trials, a decade later: Have we improved?'. Together they form a unique fingerprint.

  • Cite this